FDA-approved
Digestive & weight
Lutetium Lu-177 dotatate
Evidence
FDA approved
Class
Radiolabeled somatostatin analog (therapy)
KEY TAKEAWAY
Lutetium Lu 177 dotatate is a somatostatin-receptor-binding peptide carrying a radioactive lutetium atom. It is sold as Lutathera. The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.
Written by the Veylo editorial team · Updated
November 2026
What it is
Radiolabeled somatostatin analog (therapy)
Approved for
Neuroendocrine tumors of the gut and pancreas that carry somatostatin receptors
Key fact
The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.
Route
Intravenous infusion in a series of treatments
Evidence strength
FDA approved
Lutetium Lu 177 dotatate is a somatostatin-receptor-binding peptide carrying a radioactive lutetium atom. It is sold as Lutathera.
The peptide carries radiation directly to tumor cells that have somatostatin receptors, and the radiation damages them while sparing most other tissue.
The FDA approved Lutathera in 2018 for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and later for adolescents aged 12 and older.
Neuroendocrine tumors of the gut and pancreas that carry somatostatin receptors.
Nausea, vomiting, low blood counts and kidney effects are the main concerns. Because it is radioactive, specific radiation-safety precautions apply.
U.S. FDA prescribing information for Lutetium Lu-177 dotatate. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.